Skip to main content

Advertisement

SpringerLink
Log in

Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We aimed to assess the relative efficacy and tolerability of monotherapy with leflunomide or tacrolimus at recommended dosages in rheumatoid arthritis (RA) patients. Randomized controlled trials (RCTs) examining the efficacy and tolerability of leflunomide 20 mg, leflunomide 10 mg, tacrolimus 3 mg, tacrolimus 1.5–2 mg, and placebo, based on the number of withdrawals of RA patients, were included. We performed a Bayesian random-effects network meta-analysis to combine direct and indirect evidence from the RCTs. Six RCTs including 1510 patients met the inclusion criteria. The proportion of patient withdrawals owing to lack of efficacy was significantly lower in the leflunomide 20 mg (OR 0.17, 95% credible interval (CrI) 0.08–0.34); leflunomide 10 mg (OR 0.16, 95% CrI 0.02–0.75); and tacrolimus 3 mg (OR 0.41, 95% CrI 0.21–0.74) groups than in the placebo group. Rank probability based on the surface under the cumulative ranking curve (SUCRA) values indicated that leflunomide 20 mg had the highest probability of being the best treatment based on the number of withdrawals owing to lack of efficacy (SUCRA = 0.8530), followed by leflunomide 10 mg (SUCRA = 0.8321), tacrolimus 3 mg (SUCRA = 0.4965), tacrolimus 1.5–2 mg (SUCRA = 0.3035), and placebo (SUCRA = 0.0150). Patient withdrawals owing to adverse events did not differ significantly among the groups; however, withdrawals in the placebo group were fewer than those in the leflunomide 20 mg group (OR 0.22, 95% CrI 0.07–0.74). Placebo had the highest probability of being the most tolerable treatment (SUCRA = 0.8161) followed by tacrolimus 3 mg (SUCRA = 0.6490), tacrolimus 1.5–2 mg (SUCRA = 0.4857), leflunomide 10 mg (SUCRA = 0.4651), and leflunomide 20 mg (SUCRA = 0.0841). Leflunomide 20 mg, leflunomide 10 mg, and tacrolimus 3 mg were more efficacious than placebo, while leflunomide 20 mg was less tolerable than placebo. Leflunomide is likely to be more efficacious but less tolerable than tacrolimus for RA treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. The Lancet 388:2023–2038

  2. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug–based treatment strategies. Arthritis Rheum 39:616–622

    Article  CAS  PubMed  Google Scholar 

  3. Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:20–26

    CAS  PubMed  Google Scholar 

  4. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka J, Chin J, Hutchinson N (1989) The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143:718–726

    CAS  PubMed  Google Scholar 

  5. Lee Y, Woo J, Choi S, Ji J, Bae S, Song G (2010) Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol 39:271–278

    Article  CAS  PubMed  Google Scholar 

  6. Capell H (2002) Long term maintenance therapy with disease modifying antirheumatic drugs. J Rheumatol 66:38–43

    CAS  Google Scholar 

  7. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M (1995) Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 54:708–712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheumatism 38:1595–1603

    Article  CAS  PubMed  Google Scholar 

  9. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R, Group ELS (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353:259–266

    Article  CAS  PubMed  Google Scholar 

  10. Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–2550

    Article  CAS  PubMed  Google Scholar 

  11. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S (2004) Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 31:243–251

    CAS  PubMed  Google Scholar 

  12. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA (2003) Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial. Arthritis Rheum 48:3328–3337

    Article  CAS  PubMed  Google Scholar 

  13. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L (2002) Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 46:2020–2028

    Article  CAS  PubMed  Google Scholar 

  14. Golicki D, Newada M, Lis J, Pol K, Hermanowski T, Tlustochowicz M (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 122:22–32

    CAS  PubMed  Google Scholar 

  15. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G (2003) Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 30:1182–1190

    CAS  PubMed  Google Scholar 

  16. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ: Br Med J 331:897

    Article  Google Scholar 

  17. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D (1996) Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 276:637–639

    Article  CAS  PubMed  Google Scholar 

  18. Choy E, Smith C, Dore C, Scott D (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414–1421

    Article  CAS  PubMed  Google Scholar 

  19. Ravindran V, Scott D, Choy E (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855–859

    Article  CAS  PubMed  Google Scholar 

  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269

    Article  PubMed  Google Scholar 

  22. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3:110

    Article  PubMed  PubMed Central  Google Scholar 

  23. Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171

    Article  PubMed  Google Scholar 

  24. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A (2013) Evidence synthesis for decision making 4 Inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak 33:641–656

    Article  Google Scholar 

  25. Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98–110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285–299

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported in part by a grant of the Korea Healthcare technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI15C2958).

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Sang-Cheol Bae

  2. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul, 136-705, South Korea

    Young Ho Lee

Authors
  1. Sang-Cheol Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Young Ho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young Ho Lee.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bae, SC., Lee, Y.H. Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clin Rheumatol 37, 323–330 (2018). https://doi.org/10.1007/s10067-017-3857-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3857-5

Keywords

Search

Navigation